KIT and acute myeloid leukemia: Both quizartinib and AC886 potently inhibited the growth of wild-type FLT3 AML EOL-1 (with FIP1L-PDGFRα) cells and moderately inhibited growth of Kasumi-1 (with KIT N822K) cells, but they had minimal impact on the growth of other wild-type FLT3 AML cells.